Safracins, new antitumor antibiotics. III. Biological activity

Y Ikeda; Y Shimada; K Honjo; T Okumoto; T Munakata

doi:10.7164/antibiotics.36.1290

Safracins, new antitumor antibiotics. III. Biological activity

J Antibiot (Tokyo). 1983 Oct;36(10):1290-4. doi: 10.7164/antibiotics.36.1290.

Authors

Y Ikeda, Y Shimada, K Honjo, T Okumoto, T Munakata

PMID: 6358171
DOI: 10.7164/antibiotics.36.1290

Abstract

Safracins A and B have antibacterial activity against Gram-positive and Gram-negative bacteria in vitro but no therapeutic activity in mice infected with Staphylococcus aureus. Safracins A and B induce abnormal morphological changes in Echerichia coli cells. Tests with transplantable mice tumors demonstrate that safracins A and B inhibit the growth of P388 leukemia and IMC carcinoma.

MeSH terms

Animals
Antibiotics, Antineoplastic / toxicity*
Carcinoma / drug therapy
Drug Evaluation, Preclinical
Escherichia coli / drug effects
Female
Isoquinolines / therapeutic use
Isoquinolines / toxicity
Leukemia P388 / drug therapy
Mice
Mice, Inbred ICR
Microbial Sensitivity Tests
Species Specificity

Substances

Antibiotics, Antineoplastic
Isoquinolines
safracin A
safracin B